Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of subcutaneous alemtuzumab plus oral fludarabine in untreated CLL
2006-000741-19Phase 4Terminated
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab and fludarabine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoints: MRD response rate and Safety of alemtuzumab + fludarabine. Started Mar 2006; status: terminated.
02
Drugs
alemtuzumabfludarabine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2006-000741-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000741-19.